for the cluster reporting to the general manager. Lead, design and implement the medical strategy for all therapeutic areas. Lead and manage a Medical affairs team. • Contributed to the affiliate success, providing informed and technical decisions to the executive committee. • Establishing medical affairs as one of the main pillars of the company. Introducing MSLs on the Fertility business and growing the positions. • Developed and executed Iberia Medical strategy for Fertility, Gastroenterology, and obstetrics therapeutic areas. • Directed a team composed of MSLs and medical advisor. • Established SOPs for the development of medical affairs. Created a culture for medical grants enlarging the functions of the MSL role. • Advisor and active participant in global taskforces and work groups. Co-Creation of the global integrated brand plans for Fertility. Design of MSLs CRM and dashboards. Contribute to publications groups. • Designed and executed a CME program that enhances peer to peer interaction, with more than 40 sessions and 400 KOLs contacted. Scored NPS above 8.5. • Strong implementation of Investigator Sponsor Studies, more than five approved and one RWE that help positioning among competitors.

Medical launch lead for Mavenclad, responsible for the medical strategy and prelaunch activities. Lead the Iberian medical affairs team. reporting to the medical director. • Supervised MSLs and Medical Advisors, ensuring KOL management, quality CME programs aligned with the communication strategy. • Designed and implemented the local Medical Strategy for N&I including tactics and communications. Responsible for the Life Cycle Management (LCM) of N&I local portfolio. • Provided strategic feedback and insights to build global Integrated Brand Plan, acted as an active member of the European workshops. • Sustained cross-functional relationships with Commercial and Market Access, guaranteeing access for Mavenclad and Business Intelligence. • Achieved Best Mavenclad® successful medical performance launch across EU5. Spanish subsidiary awarded as strategic contributors for Phase III & IV Global Clinical Trial. • Achieved Award winner for special contribution to phase III clinical trial Magnify Continuum support. • Best-practice European winner, new CME activity crafted in Spain and implemented on the rest of Europe. • Designed and executed Key Phase IV study to support the life cycle of the product; 300 patients recruited in one year.

Responsible of the two main innovative areas for TEVA Neurology and respiratory. Holding responsibility for the medical affairs teams. Reporting to the affiliate medical director. • Lead the Medical Strategy for both Respiratory & CNS areas in the Iberian cluster. • Medically responsible for the life cycle management of mature treatments like Copaxone® and the launch of Teva portfolio that includes innovation in devices and new molecules like Cinqaero® and Ajovy®. • Provide leadership and strategic direction to medical advisors. • Identify key unmet needs in the field across Teva's product portfolio and align these with business opportunities and challenges as defined by the company (or commercial partners/brand team) with particular focus on External Expert engagement/interactions. • Plan the Pre-Marketing strategy for AJOVY, a key product for the neurology franchise in the Migraine therapeutic area.

Responsible for the launch of the respiratory franchise. Reporting to the cluster medical director. • Built the Iberian medical structure for the successful launch of the franchise. Team recruited and ready to act in 4 months. 6 MSLs and 2 medical advisors. • Launch TEVA Portfolio in respiratory as Medical affairs responsible for the launch of Teva portfolio that includes innovation in devices and new molecules like CINQAERO. • Developed and executed medical strategy for Respiratory portfolio within Iberian cluster, by defining key objectives for Iberian Cluster in respiratory field. • Awarded with the best Medical launch strategy for Cinqaero a monoclonal antibody indicated in severe uncontrolled eosinophilic asthma, where I co-create the protocol and lead a phase 3b study against the main competitor that positioned the molecule as the best alternative on the market. • Led national and regional advisory boards to gather insights to guide the medical strategy, two national advisory boards and five regional per year. • Formulate and implement 10 prelaunch meetings introducing eosinophilic asthma and treatments, with more than 300 KOLs attending to the sessions. • Accountable for the coordination of the partnership with ZAMBON Pharma, providing medical expertise, insights and training for the sales teams.